



# Michael Schenker

**Date of birth:** 01/01/1978 | **Nationality:** Romanian

## ● WORK EXPERIENCE

2022 – CURRENT Craiova, Romania

**HEAD OF ONCOLOGY DEPARTMENT** CLINICAL EMERGENCY COUNTY HOSPITAL

2021 – CURRENT Craiova, Romania

**UNIVERSITY DEPARTMENT HEAD** UNIVERSITY OF MEDICINE AND PHARMACY

03/2014 – CURRENT Craiova, Romania

**MD - SENIOR SPECIALIST IN MEDICAL ONCOLOGY** SF. NECTARIE ONCOLOGY CENTER

2012 – 2013 Craiova, Romania

**MD - SENIOR SPECIALIST IN MEDICAL ONCOLOGY** ONCOLAB S.R.L.

01/01/2012 – CURRENT Craiova, Romania

**MD - SENIOR SPECIALIST IN MEDICAL ONCOLOGY** CLINICAL EMERGENCY COUNTY HOSPITAL

01/01/2007 – 31/12/2011 Craiova, Romania

**MD - SPECIALIST IN MEDICAL ONCOLOGY** CLINICAL EMERGENCY COUNTY HOSPITAL

01/01/2002 – 31/12/2006 Craiova, Romania

**MD - FELLOWSHIP IN MEDICAL ONCOLOGY** CLINICAL EMERGENCY COUNTY HOSPITAL

## ● EDUCATION AND TRAINING

2018 – CURRENT Craiova,, Romania

**ASSOCIATE PROFESSOR** Oncology Department, University of Medicine and Pharmacy

**Website** <https://umfcv.ro/>

2007 – 2018 Craiova,, Romania

**LECTURER** Oncology Department, University of Medicine and Pharmacy

**Website** <https://umfcv.ro/>

2002 – 2007 Craiova,, Romania

**ASSISTANT PROFESSOR** Oncology Department, University of Medicine and Pharmacy

**Website** <https://umfcv.ro/>

Craiova,, Romania

**PHD** University of Medicine and Pharmacy

**Website** <https://umfcv.ro/> | **Field of study** Medical Oncology |

**Thesis** The role of tumoral markers in the diagnosis, prognosis evaluation, treatment monitorisation and evolution of breast cancer

1996 – 2002 Craiova,, Romania

**STUDENT** University of Medicine and Pharmacy

---

**Website** <https://umfcv.ro/>

1992 – 1996 Bălcești,, Romania

**STUDENT** Petrache Poenaru Highschool

---

1984 – 1992 Bălcești,, Romania

**STUDENT** Elementary school

---

## ● **LANGUAGE SKILLS**

---

Mother tongue(s): **ROMANIAN**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
<b>ENGLISH</b>	C2	C2	C2	C2	C2

*Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user*

## ● **DIGITAL SKILLS**

---

Good Knowledge of Microsoft Office: Word, Excel, PowerPoint | Google Suite (Doc, Slides, Form, Sheet, Drive)

## ● **ADDITIONAL INFORMATION**

---

### **PUBLICATIONS**

Kang, Y. K., M., Schenker, M. et. al. (2024). Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 10.1007/s10120-023-01455-5. Advance online publication. <https://doi.org/10.1007/s10120-023-01455-5>

Author

---

Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, et. all. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024 Feb 21;JCO2301601. doi: 10.1200/JCO.23.01601.

Author

---

Tan DSW, Felip E, de Castro G, Solomon BJ, Greystoke A, Cho BC, Cobo M, Kim TM, Ganguly S, Carcereny E, Paz-Ares L, Bennouna J, Garassino MC, Schenker M, Kim SW, Brase JC, Bury-Maynard D, Passos VQ, Deudon S, Dharan B, Song Y, Caparica R, Johnson BE. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial. J Clin Oncol. 2024 Jan 10;42(2):192-204. doi: 10.1200/JCO.23.00980. Epub 2023 Dec 1.

Author

---

Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X et. all. Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial. *J Immunother Cancer*. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189

---

Author

Thatcher, N., Goldschmidt, J. H., Thomas, M., Schenker, M., Pan, Z., Rodriguez, L. P., Breder, V., Ostoros, G., & Hanes, V. (2019). Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 25(10), 3193. <https://doi.org/10.1158/1078-0432.CCR-19-1098>

---

Author

Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Cheng Y, Sakai H, Paz-Ares L, Lu S, John T, Sun X, et all. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes. *Eur J Cancer*. 2023 Apr;183:174-187. doi: 10.1016/j.ejca.2023.01.015.

---

Author

Moehler, M., Xiao, H., Blum, S. I., Elimova, E., Cella, D., Schenker, M., Kowalyszyn, R., Hunter, S., Davenport, E., ... Wyrwicz, L. (2023). Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 41(35), 5388–5399. <https://doi.org/10.1200/JCO.23.00170>

---

Author

Lim SM, Peters S, Ortega Granados AL, Pinto GDJ, Fuentes CS, Lo Russo G, Schenker M, Ahn JS, Reck M, Szigyarto Z, Huseinovic N, Zografos E, Buss E, Stjepanovic N, O'Donnell S, de Marinis F. Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial. *Nat Commun*. 2023 Nov 11;14(1):7301. doi: 10.1038/s41467-023-42900-4.

---

Author

Diab, A., Gogas, H., Sandhu, S., Long, G. V., Ascierto, P. A., Larkin, J., Sznol, M., Franke, F., Ciuleanu, T. E., Pereira, C., Muñoz Couselo, E., Bronzon Damian, F., Schenker, M., Arriaga, Y., ... Khushalani, N. I. (2023). Bempedalsleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 41(30), 4756–4767. <https://doi.org/10.1200/JCO.23.00172>

---

Author

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, et.all. A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus. *Future Oncol*. 2023 Apr;19(11):739-752. doi: 10.2217/fo-2022-1149.

---

Author

Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Le Bret, T., Shariat, S. F., Park, S. H., Ye, D., Agerbaek, M., Enting, D., McDermott, R., Gajate, P., Peer, A., Milowsky, M. I., Nosov, A., Antonio, J. N., Jr, Tupikowski, K., ... Galsky, M. D. (2023). Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary. *Future oncology (London, England)*, 19(6), 413–426. <https://doi.org/10.2217/fo-2022-1294>

---

Author

Özgüroğlu, M., Kilickap, S., Sezer, A., Gümüş, M., Schenker, M., Cicin, I., Ho, G. F., Li, Y., Li, S., Pouliot, J. F., ... Rietschel, P. (2023). First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial. *The Lancet. Oncology*, 24(9), 989–1001. [https://doi.org/10.1016/S1470-2045\(23\)00329-7](https://doi.org/10.1016/S1470-2045(23)00329-7)

Author

---

Harrington, K. J., Ferris, R. L., Schenker, M., Bratland, Å., Walker, J. W. T., Grell, P., Coutte, A., Salas, S., Grant, C., de Azevedo, S., Soulières, D., Hansen, A. R., Wei, L., ... Haddad, R. (2023). Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. *JAMA oncology*, 9(6), 779–789. <https://doi.org/10.1001/jamaoncol.2023.0147>

Author

---

Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, Mahave M, Alexandru A, Peters S, Pluzanski A, Caro RB, Linardou H, Burgers JA, Nishio M, Martinez-Marti A, Azuma K, Axelrod R, Paz-Ares LG, Ramalingam SS, Borghaei H, O'Byrne KJ, Li L et al. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1. *J Thorac Oncol*. 2023 Aug;18(8):1055-1069. doi: 10.1016/j.jtho.2023.04.021.

Author

---

Paz-Ares LG, Ciuleanu TE, Pluzanski A, Lee JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker M, Linardou H, Caro RB, Provencio M, Zurawski B, Lee KH, Kim SW, Caserta C, Ramalingam SS, Spigel DR, Brahmer JR, Reck M, O'Byrne KJ et al. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. *J Thorac Oncol*. 2023 Jan;18(1):79-92. doi: 10.1016/j.jtho.2022.08.014. Epub 2022 Aug 30.

Author

---

Weber, J. S., Schadendorf, D., Del Vecchio, M., Larkin, J., Atkinson, V., Schenker, M., Pigozzo, J., Carlino, M. S., Di Giacomo, A. M., Butler, M. O., Muñoz-Couselo, E., ... Long, G. V. (2023). Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 41(3), 517–527. <https://doi.org/10.1200/JCO.22.00533>

Author

---

Larkin, J., Del Vecchio, M., Mandalá, M., Gogas, H., Schenker, M., Grob, J. J., Middleton, M. R., de la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A. G., Fecher, L. A., ... Weber, J. (2023). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(17), 3352–3361. <https://doi.org/10.1158/1078-0432.CCR-22-3145>

Author

---

van der Heijden, M. S., Sonpavde, G., Powles, T., Necchi, A., Burotto, M., Schenker, M., Sade, J. P., Bamias, A., Beuzeboc, P., Bedke, J., Oldenburg, J., Chatta, G., Ürün, Y., Ye, D., He, Z., Valderrama, B. P., Ku, J. H., Tomita, Y., Filian, J., Wang, L., ... CheckMate 901 Trial Investigators (2023). Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. *The New England journal of medicine*, 389(19), 1778–1789. <https://doi.org/10.1056/NEJMoa2309863>

Author

---

Shah, M. A., Udrea, A. A., Bondarenko, I., Mansoor, W., Sánchez, R. G., Sarosiek, T., Bozzarelli, S., Schenker, M., Luft, A. V., ... Ajani, J. A. (2022). Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/ Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. *Cancers*, 14(5), 1168. <https://doi.org/10.3390/cancers14051168>

Author

---

Mireștean, C. C., Stan, M. C., Schenker, M., Volovăț, C., Volovăț, S. R., Iancu, D. T. P., Iancu, R. I., & Bădulescu, F. (2023). Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers-Early Experiences from Romania and Literature Review. *Diagnostics (Basel, Switzerland)*, 13(16), 2620. <https://doi.org/10.3390/diagnostics13162620>

Author

---

Larkin J, Weber J, Del Vecchio M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Márquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, De la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, et al. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. *Eur J Cancer*. 2022 Sep;173:285-296. doi: 10.1016/j.ejca.2022.06.041

Author

---

Martin M, Hegg R, Kim SB, Schenker M, Grecea D, Garcia-Saenz JA, Papazisis K, Ouyang Q, Lacko A, Oksuzoglu B, Reeves J, Okera M, Testa L, Shimizu C, Denduluri N, Adamchuk H, Dakhil S, Wei R, Forrester T et al. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial. *JAMA Oncol*. 2022 Aug 1;8(8):1190-1194. doi: 10.1001/jamaoncol.2022.1488.

Author

---

Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, Park K, Sakai H, Ohe Y, Nishio M, Audigier-Valette C, Burgers JA, Pluzanski A, Sangha R, Gallardo C, Takeda M, Linardou H, Lupinacci L, Lee KH, Caserta C, Provencio M, Carcereny E, Otterson GA, Schenker M et al. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. *J Thorac Oncol*. 2022 Feb;17(2):289-308. doi: 10.1016/j.jtho.2021.09.010.

Author

---

Shitara, K., Ajani, J. A., Moehler, M., Garrido, M., Gallardo, C., Shen, L., Yamaguchi, K., Wyrwicz, L., Skoczylas, T., Bragagnoli, A. C., Liu, T., Tehfe, M., Elimova, E., Bruges, R., Zander, T., de Azevedo, S., Kowalyszyn, R., Pazo-Cid, R., Schenker, M., Cleary, J. M., ... Janjigian, Y. Y. (2022). Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. *Nature*, 603(7903), 942-948. <https://doi.org/10.1038/s41586-022-04508-4>

Author

---

Larkin, J., Weber, J., Schenker, M., Grob, J. J., Chiarion-Sileni, V., Middleton, M. R., De la Cruz-Merino, L., Arenberger, P., Atkinson, V., Hill, A., Fecher, L. A., Millward, M., ... Mandalá, M. (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. *European journal of cancer (Oxford, England : 1990)*, 173, 285-296. <https://doi.org/10.1016/j.ejca.2022.06.041>

Author

---

Monk, B. J., Parkinson, C., Lim, M. C., Ghamande, S., Yeku, O., Chudecka-Glaz, A., Schenker, M., Littell, R. D., Safra, T., ... Kristeleit, R. S. (2022). A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 40(34), 3952-3964. <https://doi.org/10.1200/JCO.22.01003>

Author

---

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet*. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2.

Author

Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebrecht, T., Shariat, S. F., Park, S. H., Ye, D., Agerbaek, M., Enting, D., McDermott, R., Gajate, P., Peer, A., Milowsky, M. I., Nosov, A., Neif Antonio, J., Jr, Tupikowski, K., ... Galsky, M. D. (2021). Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *The New England journal of medicine*, 384(22), 2102–2114. <https://doi.org/10.1056/NEJMoa2034442>

Author

---

Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., Uronis, H., Elimova, E., Grootsholten, C., Geboes, K., Zafar, S., Snow, S., Ko, A. H., Feeney, K., Schenker, M., Kocon, P., ... CheckMate 577 Investigators (2021). Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *The New England journal of medicine*, 384(13), 1191–1203. <https://doi.org/10.1056/NEJMoa2032125>

Author

---

Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Erratum in: *Lancet Oncol*. 2021 Mar;22(3):e92.

Author

---

Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootsholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *N Engl J Med*. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. Erratum in: *N Engl J Med*. 2023 Feb 16;388(7):672.

Author

---

Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, Selvaggi G, Baudelet C, Baden J, Pandya D, Doshi P, Kim HR. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. *J Clin Oncol*. 2021 Apr 20;39(12):1349-1359. doi: 10.1200/JCO.20.02212.

Author

---

Schenker, R. A., Schenker, M., Stovicek, P. O., Mazilu, L., Negru, Ş. M., Burov, G., & Ciurea, M. E. (2023). Comprehensive preoperative psychological assessment of breast cancer patients. *Psychology, health & medicine*, 28(2), 359–374. <https://doi.org/10.1080/13548506.2022.2059095>

Author

---

Mehedinţeanu, A. M., Sfredel, V., Stovicek, P. O., Schenker, M., Târtea, G. C., Istrătoaie, O., Ciurea, A. M., & Vere, C. C. (2021). Assessment of Epinephrine and Norepinephrine in Gastric Carcinoma. *International journal of molecular sciences*, 22(4), 2042. <https://doi.org/10.3390/ijms22042042>

Author

---

Mandala M, Larkin J, Ascierto PA, Del Vecchio M, Gogas H, Cowey CL, Arance A, Dalle S, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Lutzky J, De La Cruz-Merino L, et al. Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. *J Immunother Cancer*. 2021 Aug;9(8):e003188. doi: 10.1136/jitc-2021-003188. Erratum in: *J Immunother Cancer*. 2021 Nov;9(11)

Author

---

Ciurea, A. M., Gheonea, D. I., Schenker, M., Mehedinţeanu, A. M., Târtea, G. C., & Vere, C. C. (2021). The Prognostic Correlation of Heart Rate Variability at Diagnosis with Survival of Patients with Hepatocellular Carcinoma. *Diagnostics (Basel, Switzerland)*, 11(5), 890. <https://doi.org/10.3390/diagnostics11050890>

Author

---

Dragomir, R., Dragomir, A. S., Negru, A., Săftescu, S., Popovici, D., Schenker, M., Lupușoru, R., & Negru, Ș. (2021). Role of combining neutrophil-to-lymphocyte ratio and pretreatment body mass index in predicting progression-free survival in patients with non-small cell lung cancer treated with nivolumab. *Experimental and therapeutic medicine*, 21(5), 526. <https://doi.org/10.3892/etm.2021.9958>

Author

---

Ascierto, P. A., Del Vecchio, M., Mandalá, M., Gogas, H., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Atkinson, V., Hill, A., Fecher, L. A., Millward, M., ... Weber, J. (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. *The Lancet. Oncology*, 21(11), 1465–1477. [https://doi.org/10.1016/S1470-2045\(20\)30494-0](https://doi.org/10.1016/S1470-2045(20)30494-0)

Author

---

Redondo A, Colombo N, McCormack M, Dreosti L, Nogueira-Rodrigues A, Scambia G, Lorusso D, Joly F, Schenker M, Ruff P, Estevez-Diz M, Irahara N, Donica M, Gonzalez-Martín A. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. *Gynecol Oncol*. 2020 Oct;159(1):142-149. doi: 10.1016/j.ygyno.2020.07.026. Epub 2020 Aug 4.

Author

---

Pillai, R. N., Fennell, D. A., Kovcin, V., Ciuleanu, T. E., Ramlau, R., Kowalski, D., Schenker, M., Yalcin, I., Teofilovici, F., Vukovic, V. M., & Ramalingam, S. S. (2020). Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 38(6), 613–622. <https://doi.org/10.1200/JCO.19.00816>

Author

---

Raymond, E., Kulke, M. H., Qin, S., Yu, X., Schenker, M., Cubillo, A., Lou, W., Tomasek, J., Thiis-Evensen, E., Xu, J. M., Croitoru, A. E., Khasraw, M., Sedlackova, E., Borbath, I., Ruff, P., Oberstein, P. E., Ito, T., Jia, L., Hammel, P., Shen, L., ... Fazio, N. (2018). Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. *Neuroendocrinology*, 107(3), 237–245. <https://doi.org/10.1159/000491999>

Author

---

Fazio, N., Martini, J. F., Croitoru, A. E., Schenker, M., Li, S., Rosbrook, B., Fernandez, K., Tomasek, J., Thiis-Evensen, E., Kulke, M., & Raymond, E. (2019). Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. *Future oncology (London, England)*, 15(17), 1997–2007. <https://doi.org/10.2217/fon-2018-0934>

Author

---

Thongprasert, S., Geater, S. L., Clement, D., Abdelaziz, A., Reyes-Igama, J., Jovanovic, D., Alexandru, A., Schenker, M., Sriuranpong, V., Serwatowski, P., Suresh, S., Cseh, A., & Gaafar, R. (2019). Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study. *Lung cancer management*, 8(3), LMT15. <https://doi.org/10.2217/lmt-2019-0004>

Author

---

Reck, M., Schenker, M., Yuan, Y., Nathan, F. E., Bhagavatheeswaran, P., DeRosa, M., Taylor, F., Lawrance, R., ... Brahmer, J. (2019). Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. *European journal of cancer (Oxford, England : 1990)*, 116, 137–147. <https://doi.org/10.1016/j.ejca.2019.05.008>

Author

---

Pillai RN, Fennell DA, Kovcin V, Ciuleanu TE, Ramlau R, Kowalski D, Schenker M, Yalcin I, Teofilovici F, Vukovic VM, Ramalingam SS. Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2). *J Clin Oncol*. 2020 Feb 20;38(6):613-622. doi: 10.1200/JCO.19.00816. Epub 2019 Dec 12.

Author

Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., Makris, A., Nemsadze, G., Brunt, A. M., Kuemmel, Schenker, M., ... Cortés, J. (2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. *JAMA oncology*, 5(11), 1556–1564. <https://doi.org/10.1001/jamaoncol.2019.2526>

Author

---

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., Grob, J. J., Butler, M. O., Middleton, M. R., Maio, M., Atkinson, V., Queirolo, P., Gonzalez, R., Kudchadkar, R. R., Smylie, M., Meyer, N., ... CheckMate 238 Collaborators (2017). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *The New England journal of medicine*, 377(19), 1824–1835. <https://doi.org/10.1056/NEJMoa1709030>

Author

---

Iordache, S., Saftoiu, A., Georgescu, C. V., Ramboiu, S., Gheonea, D. I., Filip, M., Schenker, M., & Ciurea, T. (2010). Vascular endothelial growth factor expression and microvessel density--two useful tools for the assessment of prognosis and survival in gastric cancer patients. *Journal of gastrointestinal and liver diseases : JGLD*, 19(2), 135–139.

Author

---

Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenzov Y, Wu YL; ADAURA Investigators. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. *N Engl J Med*. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. PMID: 37272535.

Collaborator

---

Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, et. all; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Survival with Cemiplimab in Recurrent Cervical Cancer. *N Engl J Med*. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187.

Collaborator

---

Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, De Menezes JJ, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV; RELATIVITY-047 Investigators. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. *N Engl J Med*. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970. PMID: 34986285; PMCID: PMC9844513.

Collaborator

---

Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. *N Engl J Med*. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380.

Collaborator

---

Choueiri TK, Powles T, Burotto M, Escudier B, Boursicot MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J et al; CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.

Collaborator

---

Petrylak, D. P., de Wit, R., Chi, K. N., Schenker, M., Alekseev, B., Necchi, A., Ou, Y. C., Coskun, H. S., Su, W. P., Bedke, J., ... RANGE study investigators (2020). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. *The Lancet. Oncology*, 21(1), 105–120. [https://doi.org/10.1016/S1470-2045\(19\)30668-0](https://doi.org/10.1016/S1470-2045(19)30668-0)

Collaborator

---

Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. *N Engl J Med*. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19

---

Colaborator

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, et al; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2020 Jan;21(1):105-120. doi: 10.1016/S1470-2045(19)30668-0.

---

Colaborator

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. *N Engl J Med*. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662.

---

Colaborator

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., Yamashita, T., Lu, Y. S., Inoue, K., Takahashi, M., Pápai, Z., Longin, A. S., Mills, D., Wilke, C., Hirawat, S., Juric, D., ... SOLAR-1 Study Group (2019). Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. *The New England journal of medicine*, 380(20), 1929–1940. <https://doi.org/10.1056/NEJMoa1813904>

---

Colaborator

Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Kappeler, C., Snapir, A., Sarapohja, T., Smith, M. R., & ARAMIS Investigators (2019). Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. *The New England journal of medicine*, 380(13), 1235–1246. <https://doi.org/10.1056/NEJMoa1815671>

---

Colaborator

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., Okamoto, I., Zhou, C., Cho, B. C., Cheng, Y., Cho, E. K., Voon, P. J., Planchard, D., Su, W. C., Gray, J. E., Lee, S. M., ... FLAURA Investigators (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. *The New England journal of medicine*, 378(2), 113–125. <https://doi.org/10.1056/NEJMoa1713137>

---

Colaborator

Petrylak, D. P., Schenker, M., de Wit, R., Chi, K. NRANGE study investigators (2017). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. *Lancet (London, England)*, 390(10109), 2266–2277. [https://doi.org/10.1016/S0140-6736\(17\)32365-6](https://doi.org/10.1016/S0140-6736(17)32365-6)

---

Colaborator

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Mai, Y., Poehlein, C. H., Perini, R. F., Bajorin, D. F., ... KEYNOTE-045 Investigators (2017). Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. *The New England journal of medicine*, 376(11), 1015–1026. <https://doi.org/10.1056/NEJMoa1613683>

---

Colaborator

---

## **CONFERENCES AND SEMINARS**

08/04/2022 – 13/04/2022 – New Orleans  
**AACR Annual Meeting**

- CheckMate 848: a randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden – Speaker

07/12/2022 – 09/12/2022 – Geneva  
**ESMO Immuno-Oncology Congress**

- 2MO - First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): clinical outcomes and biomarker analyses from CheckMate 592 - Speaker

22/02/2023 – Online  
**Actualități În Sfera Cancerului De Sân**

- Speaker

12/10/2023 – 14/10/2023 – Poiana Brașov  
**Congresul Național de Oncologie**

- Speaker
- Moderator

23/06/2023 – 24/06/2023 – Iași  
**Inovație în Melanom**

- Speaker

16/06/2023 – 17/06/2023 – București  
**Conferința Societății Române de Chirurgie a Sânelui și Oncologie – ediția a VIII-a**

- Speaker

17/03/2023 – 18/03/2023 – București  
**Conferința Națională Genetică Și Oncologia – O Relație Bazată Pe Dovezi**

- Speaker
- Moderator

02/11/2022 – 06/11/2022 – Sinaia  
**27th National Congress of Romanian Society of Pneumology**

- Speaker
- Moderator

21/10/2022 – 23/10/2022 – Cluj-Napoca  
**Conferința Națională De Psiho-Oncologie, Ediția A 2-A**

- Speaker
- Moderator

21/10/2022 – 22/10/2022 – Online

**Conferința Națională Chirurgia La Interferența Cu Alte Specialități**

- Speaker

22/09/2022 – 25/09/2022 – Craiova

**Al VI-Lea Congres De Genetică Medicală Cu Participare Internațională**

- Speaker

24/06/2022 – 25/06/2022 – Online

**Inovație în Melanom**

- Speaker

07/10/2021 – 09/10/2021 – Poiana Brașov

**Congresul Național de Oncologie**

- Speaker
- Moderator

29/06/2021

**Imunoterapia Și Accesul La Tratament: Fără Întârzieri În Aprobarea Studiilor Clinice**

- Interviu

09/06/2021 – 12/06/2021 – Online

**Conferința Națională de Chirurgie**

- Speaker

15/10/2020 – 17/10/2020 – Poiana Brașov

**Congresul Național de Oncologie**

- Speaker

07/09/2018 – 08/09/2018 – Craiova

**Conferința Regională de Cancer Bronhopulmonar – Ediția A IV-A, UMF Craiova**

- Speaker

28/10/2017 – București

**Workshop – Terapii pentru MELANOM? Sau Terapii pentru PACIENT?**

- Speaker

28/09/2017 – 01/10/2017 – Poiana Brașov

**Conferința Națională de Oncologie Medicală – SNOMR**

- Comitet de organizare

**CLINICAL RESEARCH**

**An Investigational Immuno-therapy Trial of Nivolumab or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)**

---

Principal investigator

**An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274)**

---

Principal investigator

**Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)**

---

Principal investigator

**Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)**

---

Principal investigator

**Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma**

---

Principal investigator

**A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848)**

---

Principal investigator

**Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial**

---

Principal investigator

**Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation**

---

Principal investigator

**A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)**

---

Principal investigator

**A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)**

---

Principal investigator

**RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival**

---

Principal investigator

**A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma**

---

Principal investigator

**A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer**

---

Principal investigator

**A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with MIBC**

---

Principal investigator

**Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer**

---

Principal investigator

**A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III NSCLC**

---

Principal investigator

**Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma**

---

Principal investigator

**A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)**

---

Principal investigator

**A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer**

---

Principal investigator

**A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney**

---

Principal investigator

**A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma**

---

Principal investigator

**A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors - CA030-001**

---

Principal investigator

**Pan-tumour study CheckMate 8TT for long-term follow-up of cancer survivors who have participated in trials investigating nivolumab**

---

Principal investigator

**A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors**

---

Principal investigator

**A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma**

---

Principal investigator

**A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)**

---

Principal investigator

**Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC**

---

Principal investigator

**A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer**

---

Principal investigator

**Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects**

---

Principal investigator

**EPIK-B5: Phase III Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With HR-positive,HER2-negative Advanced Breast Cancer With a PIK3CA Mutation, Who Progressed on or After Aromatase Inhibitor and a CDK4/6 Inhibitor**

---

Principal investigator

**KonTRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer**

---

Principal investigator

**A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy**

---

Principal investigator

**First-line (1L) Maintenance Therapy With Niraparib (nira) + Pembrolizumab (pembro) vs Placebo + Pembro in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): Phase 3 ZEAL-1L Study**

---

Principal investigator

**Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)**

---

Principal investigator

**Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced NSCLC Who Have Progressed on Prior Anti-Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy**

---

Principal investigator

**R3767-ONC-2011: A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma**

---

Principal investigator

**Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, N+, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer**

---

Principal investigator

**A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (CYCLONE 2)**

---

Principal investigator

**A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3)**

---

Principal investigator

**Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence**

---

Principal investigator

**Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)**

---

Principal investigator

**Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)**

---

Principal investigator

**Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)**

---

Principal investigator

**A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)**

---

Principal investigator

**Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)**

---

Principal investigator

**Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)**

---

Principal investigator

**Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)**

---

Principal investigator

**Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)**

---

Principal investigator

**Lenvatinib in Combination With Pembrolizumab vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy**

---

Principal investigator

**Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 Tumor Proportion Score (TPS)  $\geq$ 50%**

---

Principal investigator

**Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)**

---

Principal investigator

**A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)**

---

Principal investigator

**A Study of Pembrolizumab in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma**

---

Principal investigator

**A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)**

---

Principal investigator

**Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)**

---

Principal investigator

**Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)**

---

Principal investigator

**A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)**

---

Principal investigator

**Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)**

---

Principal investigator

**Study of Pembrolizumab/Vibostolimab in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer**

---

Principal investigator

**Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)**

---

Principal investigator

**A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer**

---

Principal investigator

**A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma**

---

Principal investigator

**A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)**

---

Principal investigator

**A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)**

---

Principal investigator

**Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]**

---

Principal investigator

**A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (EL1SSAR)**

---

Principal investigator

**A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)**

---

Principal investigator

**A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (IidERA Breast Cancer)**

---

Principal investigator

**Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma**

---

Principal investigator

**A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)**

---

Principal investigator

**A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases**

---

Principal investigator

**A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)**

---

Principal investigator

**A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100)**

---

Principal investigator

**Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)**

---

Principal investigator

**A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)**

---

Principal investigator

**A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)**

---

Principal investigator

**A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)**

---

Principal investigator

**Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)**

---

Principal investigator

**Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)**

---

Principal investigator

**A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Cirrhosis**

---

Principal investigator

**Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)**

---

Principal investigator

**Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)**

---

Principal investigator

**Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)**

---

Principal investigator

**Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)**

---

Principal investigator

**Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer**

---

Principal investigator

**A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)**

---

Principal investigator

**Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)**

---

Principal investigator

**A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)**

---

Principal investigator

**A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive**

---

Principal investigator

**A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma**

---

Principal investigator

**A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery**

---

Principal investigator

**A Multicenter, Prospective Study To Evaluate Actionable Alterations Detected By F1 CDX/F1L CDX In Patients With Non-Small Cell Lung Cancer (NSCLC)**

---

Principal investigator

**A phase 3 trial of fianlimab (anti-LAG-3) plus cemiplimab (anti-PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.**

---

Principal investigator

**Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)**

---

Principal investigator

**NETWORKS AND MEMBERSHIPS**

**European Society for Medical Oncology**

- Member

**American Society of Clinical Oncology**

- Member

2019 – CURRENT

**Oncology Committee of the Ministry of Health**

- President
- 

18.02.2026